Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$5.9B
348M shares
52-week range
$9.49 – $19.26
78% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
1.8
EV / FCF (TTM)
99.6
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
www.amneal.comNo one on the platform currently holds AMRX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 276,637 | $3.4M |
| Execution date | Ratio |
|---|---|
| 2013-08-26 | 1-for-25reverse |
No one on the platform has traded AMRX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 15.5% | — | — | — | ||
| Rev. Growth % | 8.0% | 8.7% | ||||
| Profit Margin % | 2.4% | -2.1% | -0.2% | |||
| Free Cash Flow Margin % | 8.9% | 7.3% | 6.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +9.3% on the P/E track.
At today's price, your expected annual return is +14.7% on the P/E track.
At today's price, your expected annual return is +19.2% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3.2B | +4.7% | $1.01 | $1.00–$1.03 | 16.9× | 3 |
| 2027 | $3.4B | +9.0% | $1.17 | $1.01–$1.33 | 14.6× | 3 |
| 2028 | $3.8B | +10.9% | $1.45 | $1.43–$1.47 | 11.8× | 1 |
| 2029 | $4.4B | +15.4% | $1.83 | $1.80–$1.85 | 9.3× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $0.22 | $0.30 | +34.8% |
| 2026-05-07 | $0.17 | $0.27 | +58.8% |
| 2026-02-27 | $0.18 | $0.21 | +16.7% |
| 2025-10-30 | $0.13 | $0.17 | +30.8% |
| 2025-08-05 | $0.18 | $0.25 | +38.9% |
| 2025-05-02 | $0.15 | $0.21 | +40.0% |
| 2025-02-28 | $0.15 | $0.12 | -20.0% |
| 2024-11-08 | $0.13 |
| $0.16 |
| +23.1% |
| $6.5B |
| — |
| MIRMMirum Pharmaceuticals, Inc. | $96.75 | -1.50% | $5.9B | — |
| NVSTEnvista Holdings Corp | $25.79 | +0.94% | $4.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Oppenheimer reitd $XERS OP-$18/said--Yesterday's virtual event provided an overview of Xeris Biopharma's clinical, regulatory, and commercial plans for XP-8121, its once-weekly subcutaneous levothyroxine candidate for hypothyroidism. $ABBV $AMRX SNY PFE MRK Oppenheimer added —In our view, KOL commentary and the design of the soon-to-begin Phase 3 Cornerstone trial derisk XP-8121's opportunity, aimed at the 3-5M US patients who remain biochemically uncontrolled on oral levothyroxine. The concurrent Touchstone trial will provide additional real-world evidence of unmet need and clinical differentiation from standard of care. We see XP-8121 launching in 2030, and management estimated a $1-3B peak sales opportunity for XP-8121 with up to 10% penetration of the target population over time. Reiterate Outperform.
View on StockTwits ↗
StochAlpha Daily - Top 5 Buys / Sells $ETON $AMRX $MSM $DRS $MTCH
View on StockTwits ↗
TUE 8/11: $AMRX – SELLING (ALL) P/L: -$670.51 -6.7% 9:58 AM – Selling all my AMRX shares this morning, and here’s why. The stock recently broke below its 10 DMA, which was the first technical violation. It then fell below our noted ROUND-$18 support, and shares are continuing lower this morning while the 10 DMA is now clearly rolling over. With multiple signs of technical deterioration stacking up, I’m exiting the position and moving on. James’ Trader’s Tip: Ongoing Technical Weakness Is a Signal • A break below the 10 DMA is often the first warning that momentum is deteriorating. • Losing additional support levels confirms that the weakness is continuing—not improving. • When the 10 DMA begins rolling over while price continues lower, the stock is telling you the technical trend is weakening. Listen to it. https://buyingbreakouts.com/tue-8-11-amrx-selling-all-p-l-670-51-6-7/
View on StockTwits ↗
$PMN Platform strategy The real jackpot: PMN267 + PMN442 ProMIS describes three key antibody programs: PMN310 → Alzheimer's disease / Amyloid-ß oligomers => PMN310 potential $5-10 bn * PMN267 → ALS / misfolded TDP-43 => PMN267 potential $1-3 bn * PMN442 → Parkinsons disease, MSA, => PMN442 potential $1-3 bn and other synucleinopathies Other Platforms potential $0,5-2 bn means in total range from 7.5-18 bn with a potential Share price of => $405 to $970 This is not pure fantasy. $ABBV $TEVA $AMRX
View on StockTwits ↗
Wall St is expecting 0.23 EPS for $AMRX Q3 [Reporting 10/29 BMO] http://www.estimize.com/intro/amrx?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗$AMRX reported 0.30 EPS and 796.20 revenue for Q2. http://www.estimize.com/intro/amrx?chart=historical&metric_name=eps&utm_content=AMRX&utm
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-7-30-amneal-pharmaceuticals-inc-stock-1/ $AMRX Amneal Pharmaceuticals Earnings Transcript
View on StockTwits ↗$PMN buyout candidates are also $ABBV $TEVA $$AMRX for Parkinson
View on StockTwits ↗
$AMRX Q2 2026 Net Revenue of $796 million GAAP Net Income of $58 million Diluted Income per Share of $0.18 Adjusted EBITDA of $206 million; Adjusted Diluted EPS of $0.30 – Raising Full 2026 Guidance Reduction in debt refinancing https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Reports-Second-Quarter-2026-Financial-Results/default.aspx
View on StockTwits ↗
$AMRX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.18 up 157.14% YoY • Reported revenue of $796.2M up 9.89% YoY • Amneal Pharmaceuticals raised its full-year 2026 guidance, now expecting net revenue of $3.10 billion - $3.20 billion, adjusted EBITDA of $750 million - $780 million, and adjusted diluted EPS of $0.96 - $1.06.
View on StockTwits ↗
$AMRX upcoming 100% Trump tariff on imported generics would be good for Amneal’s USA based manufacturing. My estrogen patch is back ordered AGAIN - no supply ✋.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.